Recent Press Releases

BOTOX Allergan's botulinum toxin type A recommended  

Allergan Launches First EU Public Awareness & Education Campaign on the Importance of Quality in Medical Aesthetics  

Allergan Reports First Quarter 2012 Operating Results  

BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval  

Allergan Announces Quarterly Conference Call  

Allergan Announces Positive Top-Line Results from Phase III BOTOX® Overactive Bladder Program  

U.S. Federal Court Finds in Favor of Allergan, Inc. and Issues Permanent Injunction against Merz Pharmaceuticals and Merz Aesthetics  

Allergan Announces Research & Development Technology Review  

Allergan Reports Fourth Quarter 2011 Operating Results  

Allergan Announces Quarterly Conference Call  

Allergan Reassures Patients and Surgeons of the Quality and Safety of Its Breast Implant Devices Sold and Distributed Worldwide  

Health Canada approves BOTOX® as prophylactic treatment for chronic migraine  

Allergan Reports Third Quarter Operating Results  

Award-winning Actress Courtney Thorne-Smith and Allergan, Inc. Reveal Changes in Women's Perceptions of BOTOX Cosmetic Over Nearly a Decade  

Allergan Announces Quarterly Conference Call  

National Headache Foundation, HealthyWomen and Allergan Offer People Living With Chronic Migraine a Chance to "Rewrite Your Day"  

BOTOX® (onabotulinumtoxinA) Receives U.S. FDA Approval for the Treatment of Urinary Incontinence in Adults with Neurological Conditions Including Multiple Sclerosis and Spinal Cord Injury  

Allergan's BOTOX® Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury  

Allergan Reports Second Quarter 2011 Operating Results  

Allergan, Inc. to Acquire Privately Held Dermatologic Company, Vicept Therapeutics